Evidence map›Paper›PMID 37397816›Full record

ArticleCurrent research in neurobiology2023

Maresin-2 inhibits inflammatory and neuropathic trigeminal pain and reduces neuronal activation in the trigeminal ganglion.

Raphael Vieira Lopes, Darciane Favero Baggio, Camila Rodrigues Ferraz, Mariana Marques Bertozzi, Telma Saraiva-Santos, Waldiceu Aparecido Verri Junior, Juliana Geremias Chichorro

Abstract read
In one paragraph

Article in Current research in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Maresins.Biomolecules · 2026
    Review
  2. Observational
  3. Review
  4. Article
  5. Review
  6. CaThe journal of headache and pain · 2024
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raphael Vieira LopesDepartment of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil.
Darciane Favero BaggioDepartment of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil.
Camila Rodrigues FerrazLaboratory of Pain, Inflammation, Neuropathy and Cancer, Department of Pathology, State University of Londrina, Londrina, PR, Brazil.
Mariana Marques BertozziLaboratory of Pain, Inflammation, Neuropathy and Cancer, Department of Pathology, State University of Londrina, Londrina, PR, Brazil.
Telma Saraiva-SantosLaboratory of Pain, Inflammation, Neuropathy and Cancer, Department of Pathology, State University of Londrina, Londrina, PR, Brazil.
Waldiceu Aparecido Verri JuniorLaboratory of Pain, Inflammation, Neuropathy and Cancer, Department of Pathology, State University of Londrina, Londrina, PR, Brazil.
Juliana Geremias ChichorroDepartment of Pharmacology, Biological Sciences Sector, Federal University of Parana, Curitiba, Parana, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pain is a common symptom associated with disorders involving the orofacial structures. Most acute orofacial painful conditions are easily recognized, but the pharmacological treatment may be limited by the adverse events of current available drugs and/or patients' characteristics. In addition, chronic orofacial pain conditions represent clinical challenges both, in terms of diagnostic and treatment. There is growing evidence that specialized pro-resolution lipid mediators (SPMs) present potent analgesic effects, in addition to their well characterized role in the resolution of inflammation. Maresins (MaR-1 and MaR-2) were the last described members of this family, and MaR-2 analgesic action has not yet been reported. Herein the effect of MaR-2 in different orofacial pain models was investigated. MaR-2 (1 or 10 ng) was always delivered via medullary subarachnoid injection, which corresponds to the intrathecal treatment. A single injection of MaR-2 caused a significant reduction of phases I and II of the orofacial formalin test in rats. Repeated injections of MaR-2 prevented the development of facial heat and mechanical hyperalgesia in a model of post-operative pain in rats. In a model of trigeminal neuropathic pain (CCI-ION), repeated MaR-2 injections reversed facial heat and mechanical hyperalgesia in rats and mice. CCI-ION increased c-Fos positive neurons and CGRP

Indexed as

c-FosCGRPChronic constriction injury of the infraorbital nerveFormalin testHyperalgesiaIntraoral incisionMiceRatsSpecialized pro-resolution lipids

Identifiers

PMID37397816
PMCPMC10313899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.